Positron Emission Tomography (PET) imaging of neurodegenerative biomarkers in people ‘at risk’ for dementia

Not Applicable

• Conditions: Subjective memory complaints; mild cognitive impairment; Dementia; Neurological - Dementias; Neurological - Neurodegenerative diseases

• Registration Number: ACTRN12622000274774
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-02-14
• Last Update Posted: 21 February 2022

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

1.Adults aged between 50 and 90 years
2.Referred due to concerns about new onset of mood or cognitive problems (within the last 5-years) that are not due to other medical conditions
3.A MMSE score of greater than or equal to 20 (a widely used screening tool).
4.Willingness to give written informed consent and willingness to participate and comply with the study.
5.Have undergone the full Healthy Brain Ageing clinic assessment protocol including the collection of blood for genotyping.
6.Willing to undergo PET scanning within one month of Healthy Brain Ageing clinic assessment.
7.Subject to available funding.
8.Considered appropriate candidate by the treating clinician.

Exclusion Criteria

1.Prior head injury (with loss of consciousness of greater than 30min)
2.Stroke
3.Major non-affective mental health disorder such as schizophrenia, Bipolar Disorder, ADHD, Autism, PTSD, chronic fatigue syndrome or acute psychosis
4.Major neurological condition such as Parkinson’s disease, epilepsy
5.Current or past alcohol or substance misuse
6.Intellectual disability
7.Currently taking benzodiazepines
8.Currently taking antipsychotics
9.Currently consuming more than 14 standard drinks of alcohol per week
10.Females who have not yet undergone menopause
11.A history of cancer diagnosis within the past 5 years
12.Current or prior kidney disease or any history of poor renal function that in the opinion of the investigator may deem it unsafe to participate in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Global Amyloid (Aß) burden as assessed by the Standardized uptake values ratios average of the area-weighted mean of frontal, superior parietal, lateral temporal, and posterior cingulate regions.[Baseline];Global Tau burden as assessed by the Standardized uptake values ratios average of the area-weighted mean of frontal, superior parietal, lateral temporal, medial temporal lobes, and posterior cingulate regions.[Baseline]